Biotechnology Innovation Organization (BIO) on Monday announced the resignation of its CEO, molecular immunologist Dr. Michelle McMurry-Heath, after confirming over the weekend that she was on a leave of absence. BIO is the trade association and top lobbying group for
…
The 340B program “has always been uniquely federal in nature” and “there is no room for states, pharmacies, or other interests to step in and try to supplant” the federal government’s exclusive control over it, the brand drug industry said
…
Genentech CEO Alexander Hardy on Tuesday urged healthcare leaders to reform the 340B program together in the wake of the recent New York Times exposé about a Virginia health system’s alleged misuse of the 340B program.
“As leaders in healthcare,
…
The U.S. Department of Health and Human Services Office of Inspector General (HHS OIG) has informed a bipartisan group of House lawmakers that the enforcement agency does not plan to impose civil monetary penalties against the drug makers that have
…
In a big victory for 340B hospitals, a federal judge in Washington, D.C. ruled yesterday that the government must immediately begin to pay 340B hospitals the full Medicare Part B drug payment rate for the remainder of calendar year (CY)
…
Government health officials need to take immediate action to fully enforce the law against drug makers who are denying 340B drug discounts to providers who use contract pharmacies to dispense 340B-priced drugs, U.S. Senator Joe Manchin (D-W.VA.) and U.S. Senator
…
CVS Health Corp. has asked a New York state court to dismiss the state’s antitrust lawsuit alleging that the pharmacy chain is forcing the state’s 340B covered entities to use its 340B third party administrator Wellpartner as a condition for
…
The U.S. Health Resources Services Administration (HRSA) has ordered South Carolina-based VistaPharm, a manufacturer of generic and over-the-counter (OTC) drugs to repay overcharges to 340B covered entities after a HRSA audit showed the company did not offer its products at the
…
Sparked by the dismissal of its complaint against Astra Zeneca and Sanofi by the government’s Administrative Dispute Resolution Panel (ADR), the National Association of Community Health Centers say “they cannot wait any longer for a solution,” to the two-year standoff
…
×
*Sign up for news summaries and alerts from 340B Report